biostudies-literatureUnknown15(8)Wang CGlioblastoma (GBM) is an aggressive primary brain tumor with a poor prognosis following conventional therapeutic interventions. Moreover, the blood-brain barrier (BBB) severely impedes the permeation of chemotherapy drugs, thereby reducing their efficacy. Consequently, it is essential to develop novel GBM treatment methods. A novel kind of pericyte immunotherapy known as chimeric antigen receptor T (CAR-T) cell treatment uses CAR-T cells to target and destroy tumor cells without the aid of the antigen with great specificity and in a manner that is not major histocompatibility complex (MHC)-restricted. It has emerged as one of the most promising therapy techniques with positive clinical outcomes in hematological cancers, particularly leukemia. Due to its efficacy in hematologic cancers, CARCancers2351https://www.ebi.ac.uk/biostudies/studies/S-EPMC10136592biostudies-literatureGene Targets of CAR-T Cell Therapy for Glioblastoma.PMC10136592Li YWang CZhang YQiu SZhang XGu LZhu HChen RFeng SJian ZXiong XfalseGene Targets of CAR-T Cell Therapy for Glioblastoma.Glioblastoma (GBM) is an aggressive primary brain tumor with a poor prognosis following conventional therapeutic interventions. Moreover, the blood-brain barrier (BBB) severely impedes the permeation of chemotherapy drugs, thereby reducing their efficacy. Consequently, it is essential to develop novel GBM treatment methods. A novel kind of pericyte immunotherapy known as chimeric antigen receptor T (CAR-T) cell treatment uses CAR-T cells to target and destroy tumor cells without the aid of the antigen with great specificity and in a manner that is not major histocompatibility complex (MHC)-restricted. It has emerged as one of the most promising therapy techniques with positive clinical outcomes in hematological cancers, particularly leukemia. Due to its efficacy in hematologic cancers, CAR2023-01-01T00:00:00Z2023 Apr2025-04-18T17:34:56.444Z2024-11-14T12:01:32.016ZS-EPMC101365923719028010.3390/cancers15082351